Because multiple drugs that positively or negatively modulate HSF1 activity are currently being tested in clinical trials for cancer and neurodegenerative diseases, it will be interesting to evaluate whether these drugs have positive or negative effects for the host in the context of viral infections, potentially serving as novel strategies to counteract viral replication in the infected individual. Here, HSF1 is linked to neurodegenerative disease.